Pactiv Evergreen Inc. Announces Receipt of All Required Regulatory Approvals for Planned Acquisition by Novolex
1. Pactiv Evergreen confirms acquisition by Novolex for $18.00 per share. 2. Transaction expected to close by April 1, 2025. 3. Pactiv Evergreen will become privately held post-transaction. 4. Financial and legal advisors are Goldman Sachs and Lazard Frères. 5. Shareholders advised to review SEC filings regarding the acquisition.